Table 3.
Outcomes of patients treated first with imatinib
| Study/Source | Imatinib dose, mg | No. of patients | High-risk patients (Sokal/Euro) | OS | PFS | EFS | AT | Follow-up, y |
|---|---|---|---|---|---|---|---|---|
| IRIS18,19 | 400 | 553 | 18% (S) | 85% | 92% | NR | 8 y | 6 (minimum) |
| Hammersmith21,22 | 400 | 204 | 29% (S) | 83% | 83% | 63% | 5 y | 3.2 (median) |
| Houston25 | 400 (19%) / 800 (81%) | 258 | 8% (S) | 97% | 92% | NR | 5 y | 4.4 (median) |
| PETHEMA27 | 400 | 210 | 16% (S) | 97% | 94% | 71% | 5 y | 4.2 (median) |
| Czech registry30 | 400 | 343 | 22% (S) | 88% | 90% | NR | 5 y | 3.8 (median) |
| French SPIRIT28 | 400 (50%) / 600 (50%) | 319 | 24% (S) | NR | 92% | NR | 5 y | NR |
| GIMEMA29 | 400 (76%) / 800 (24%) | 559 | 22% (S) | 90% | 87% | 65% | 5 y | 5.0 (median) |
| German CML STUDY IV31 | * | 1551 | 12% (E) | 88% | 86% | NR | 6 y | 5.6 (median) |
| Seoul, St. Mary Hospital32 | 400 (83%) | 363 | 22% (S) | 94% | 88% | NR | 7 y | 5.3 (median) |
| 6-800 (17%) |
EFS, event-free survival, where events are death, progression to AP or BP, failure, and treatment discontinuation for any reason, whichever comes first; med, median; min, minimum; NR, not reported; OS, overall survival; PFS, survival free from progression to AP or BP.
*
Imatinib 400 + IFNα (28%), imatinib 800 (27%), imatinib 400 (26%), imatinib 400 + low-dose arabinosyl cytosine (10%), imatinib 400 after IFNα (8%).